A lthough reviews have been recently published, there exists a paucity of guidelines or evidencebased recommendations for the management of posthemorrhagic hydrocephalus (PHH) Object. The objective of this systematic review and analysis was to answer the following question: What are the optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants?
cording to 2007 data provided by the Division of Vital Statistics of the Centers for Disease Control and Prevention (CDC), infants born with very low birth weight and gestational age have a significantly higher risk of mortality. 49 In fact, more than 50% of all infant deaths in 2007 occurred in infants born before 32 weeks' gestation. 49 In 2008, the reported preterm birth rate declined for the second consecutive year to 12.3%, but this decrease primarily involved those infants born in the later preterm period (34-36 weeks) . 47 Low birth weight (LBW) also contributes to increased infant mortality, and the CDC has reported that the percentage of LBW infants, or infants born weighing less than 2500 g, increased by 24% between 1984 and 2006. 47 A recent study of 15,454 extremely low birth weight (ELBW) infants, each weighing between 401 g and 1000 g, was undertaken to assess neurodevelopmental outcome. 1 More than 5000 infants died while in the hospital or before the follow-up visit. Among the 7693 children in whom follow-up studies were available, 2530 (33%) had a history of intraventricular hemorrhage (IVH). The IVH was Grade III or IV for 998 (13%) of the 7693 infants. Remarkably, in only 246 (3%) of the 7693 ELBW infants with follow-up was a shunt placed for PHH. 1 There are still many questions about the optimal time to intervene for infants with PHH, and there are many different opinions about the best temporizing mechanism for symptomatic infants too small or unstable for permanent shunt placement.
The objective of this systematic review and analysis was to answer the following question: What are the optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants? We evaluated the current literature and constructed evidence-based recommendations supported by the strength of the available data for the management of PHH in premature infants. Specifically, we wanted to investigate relevant evidence for the following:
• Use of surgical temporizing methods such as ventricular reservoirs, external ventricular drains (EVDs), ventriculosubgaleal (VSG) shunts, and lumbar punctures (LPs).
• Routine use of serial LPs to reduce the need to shunt or to avoid the progression of hydrocephalus in premature infants.
• Use of intraventricular thrombolytic agents, including tissue plasminogen activator (tPA), urokinase, and streptokinase, to reduce the need for shunt placement in premature infants with PHH.
• Use of acetazolamide or furosemide to reduce the need for shunt placement in premature infants with PHH.
• Efficacy of endoscopic third ventriculosomy (ETV) in this population.
• Specific CSF parameters to direct the timing of shunt placement in premature infants with PHH.
Methods

Search Criteria
Both the US National Library of Medicine and the Cochrane Database of Systematic Reviews were queried using MeSH headings and key words relevant to PHH.
Key Words. The following key words were used in this study: (((preterm 
Strategy
Two hundred thirteen abstracts were reviewed, after which 98 publications that met the inclusion criteria were selected. In addition to the overall inclusion/exclusion criteria specified in the Methods section of the Guidelines (Part 1), additional inclusion criteria included studies in which infants younger than 12 months with all forms of hydrocephalus-both congenital and acquired-were evaluated to ensure that the maximum number of studies were reviewed. The analysis focused on studies evaluating infants with PHH because of the treatment strategies and challenges unique to this patient population.
As a result of the US National Library of Medicine's search engine functionalities, additional search terms (heart ventricles) not relevant to topics addressed in this chapter were added to the search strategy. Although these search terms remained in the search strategy, we did not recall any references retrieved using them for full-text review. We excluded those references because they were not relevant to the overall scope of this project or the patient population addressed in this chapter and, therefore, did not meet the article inclusion criteria specified in the methodology section of this guideline (Part 1). 23 Following an evidentiary analysis and a review of the 98 full-text articles, 68 publications were accepted for inclusion in the evidentiary table and 30 publications were excluded. 2, 7, [12] [13] [14] 21, 22, 27, 30, 33, 35, 38, 48, [50] [51] [52] [53] 55, 57, 58, [62] [63] [64] [66] [67] [68] 70, 73, 75 The evidentiary table was assembled linking recommendations to the strength of the evidence (Levels I-III).
Search Results
Of the 98 full-text articles selected for review, 30 full-text publications were rejected based on the criteria listed above and only 68 articles were used to construct the evidentiary table (Fig. 1) . The criteria for the decision to treat were quite variable among different institutions and different study groups. For example, we evaluated 1 Class II study in which hydrocephalus was defined as the atrium of the lateral ventricle measuring > 10 mm on the horizontal plane of a head ultrasound (HUS) study or the body of the lateral ventricle at the level of the midthalamus measuring > 10 mm on a sagittal ultrasound image. J Neurosurg: Pediatrics / Volume 14 / November 2014 alus was defined as anterior cortical mantle thickness < 20 mm at an average postnatal age of 21 days along with increasing occipitofrontal circumference (OFC) as an indicator of hydrocephalus that should be treated. 5 Bada et al. 5 reported that of 10 infants requiring shunts, 5 (50%) experienced normal development, which was defined by physical and neurological assessment and evaluation using the Denver developmental screening tool. Evan's ratio, which is described as the lateral measurement of the ventricle across the frontal horns divided by the lateral measurement across the brain (biparietal diameter; also known as the ventricular/biparietal [V/BP] ratio) can also be used to describe the severity of PHH. 16 The majority of studies that were evaluated based on an initial diagnosis of PHH on HUS, CT, and MRI studies were also used. Choudhury described mild hydrocephalus as a V/ BP ratio of 0.26-0.40, moderate hydrocephalus as a V/ BP ratio of 0.40-0.60, severe hydrocephalus as a V/BP ratio of 0.60-0.90, and extreme hydrocephalus as a V/ BP ratio of 0.91-1.0. 16 These authors also reported that the thickness of the cortical mantle was not a statistically significant indicator of outcome because several infants with extreme hydrocephalus displayed normal motor development. 16 One Class II and 1 Class III study indicated that when ventriculoperitoneal (VP) shunts were placed, even in cases of severe or extreme hydrocephalus, there were some infants with normal development and motor outcome (50 of 82 patients in the Choudhury study). 5, 16 Numerous studies have reported that good neurodevelopmental outcomes may be seen if and when infants with hydrocephalus are aggressively treated and cortical mantle thickness is restored.
Results
Surgical Temporizing Measures
RecommendAtion: Ventricular access devices (VADs), external ventricular drains (EVDs), ventriculosubgaleal (VSG) shunts, or lumbar punctures (LPs) are treatment options in the management of PHH. Clinical judgment is required. StRength of RecommendAtion: Level II, moderate degree of clinical certainty.
RecommendAtion: The evidence demonstrates that VSG shunts reduce the need for daily CSF aspiration compared with VADs. StRength of RecommendAtion: Level II, moderate degree of clinical certainty.
The evidence demonstrates that VADs reduce morbidity and mortality compared with EVDs. Three Class II and 7 Class III studies were included as evidence to support the first recommendation, and these lower-quality studies documented the safety and efficacy of VADs, or Ommaya reservoirs, for the aspiration of CSF, ventricular decompression, and lowering of intracranial pressure. 3, 8, 11, 25, 26, 29, 31, 39, 78, 80 The authors of 2 Class II studies reported that ventricular reservoirs may reduce the incidence of shunt infection as well as noninfectious shunt complications. 8, 26 In one Class II study and one class III study, repeated aspiration of CSF from a VAD did not significantly increase the risk of infection. 26, 39 Three Class III studies reported that ventricular reservoirs did not significantly reduce the need for permanent shunt placement. 29, 31, 78 One Class III study reported that the use of VADs, compared with the use of continuous ventricular drainage, significantly reduced morbidity and mortality rates that were associated with the surgical treatment of PHH in LBW infants with reservoirs, instead of EVDs (Table 1) . 26 The placement of an EVD has also been used to treat hydrocephalus in preterm infants with PHH and is an option for these children, as shown in 1 Class II and 7 Class III studies. 9, 17, 28, 36, 40, 59, 60, 69 Three Class III studies reported that an EVD obviated the need for VP shunt placement in fewer than one-third of infants treated. 9, 40, 60 More than 50% of preterm infants with PHH did require permanent VP shunt placement following removal of an EVD (95 out of 132 survivors required a shunt). 9, 40, 59, 60, 69 It has been reported that placement of a VSG shunt may reduce the need for permanent shunt placement. The authors of Class II and Class III studies reported trends toward shunt independence, but the studies only enrolled 32 and 95 patients, respectively, and the results were not statistically significant. 41, 43 In their report of a Class II, retrospective historical cohort study, Lam and Heilman demonstrated that VSG shunting significantly reduced the need for daily CSF aspiration, which may decrease the risk of introducing a de novo CSF infection. 41 A chisquare test performed on their data indicated that a VSG shunt did significantly reduce the need for daily CSF aspiration when compared with a VAD (c 2 = 19.2, df = 1, p = 0.000016, p < 0.05). 41 This may reduce the risk of infection or other complications. A larger, prospective study reported a statistically significant decreased need for permanent CSF diversion in infants treated with VSG shunts. 43 This study reported that 66% of infants (20 of 30) treated with VSG shunts required VP shunts and 33% (10 of 30) remained shunt free; this was compared with a group of infants treated with VADs in which 75% (49 of 65) required VP shunts and only 25% of infants (16 of 65) remained shunt free. 43 In 2 studies, 1 intervention was compared to another with specific recommendations about the timing of the intervention for temporizing measures for the treatment of PHH in very LBW infants. In 1 Class III study, the authors compared early versus late intervention, as assessed by ventricular dilation in 5 collaborating neonatal centers. 18 Ninety-five patients were subdivided into early intervention or late intervention groups, depending on their ventricular index at the time of initial treatment. Early treatment was safe and effective regardless of whether LP and/or reservoir placement was used. Early intervention was associated with a reduced requirement for a VP shunt (OR = 0.22) and reduced risk of moderate-to-severe disability. 18 Additionally, there was a single Class III observational study of outcomes in which LPs, EVD, VSG shunts, and reservoirs were used. 57 All interventional studies were found to be safe and effective. 57 
Routine Use of Serial Lumbar Puncture
RecommendAtion: The routine use of serial lumbar puncture (LP) is not recommended to reduce the need for shunt placement or to avoid the progression of hydrocephalus in premature infants. StRength of RecommendAtion: Level I, high degree of clinical certainty.
One Class I study was included, and it reported no statistical differences in outcomes of preterm infants with PHH treated with observation alone or infants treated with daily LP (Table 2) . 4 Lumbar puncture is often used early in the treatment of PHH, despite the fact that there is no statistically significant reduction in the need for a shunt or progression of PHH. 4, 54 In fact, LP neither predicts nor prevents the need for a permanent VP shunt. 36 A second study, a Class III study, also reported no difference in adverse outcome regardless of whether infants were untreated or treated with serial LP. 15 Without aggressive treatment of hydrocephalus and with persistent ventricular dilation, outcome was poor. 15 Additionally, there was a single Class III study that concluded that repeated LPs may cause or contribute to subsequent shunt infection. 6 Although LP may be useful for drawing off CSF as an immediate treatment for elevated intracranial pressure in infants with PHH, or for sampling CSF, we do not recommend the routine use of LP to eliminate the need for a VP shunt. 15 
Nonsurgical Temporizing Agents
Intraventricular Thrombolytic Agents. RecommendAtion: Intraventricular thrombolytic agents including tissue plasminogen activator (tPA), urokinase, or streptokinase are not recommended as methods to reduce the need for shunt placement in premature infants with PHH. StRength of RecommendAtion: Level I, high clinical certainty.
Based on 1 high-quality Class I study, the DRIFT procedure-DRainage, Irrigation, and Fibrinolytic Therapy (intraventricular tPA)-is not recommended for PHH. 71 DRIFT did not significantly reduce shunt surgery or death, but it was associated with an increased rate of secondary IVH (Table 3) . 71 Forty-four percent (15 of 34) of infants in the DRIFT group died or required a shunt, compared with 50% (19 of 36) of infants who received standard treatment. Thirty-five percent (12 of 34) of preterm infants in the DRIFT study had secondary IVH, compared with 8% (3 of 34) who received standard treatment. 71 These results differ from those of earlier Class II and Class III studies in which a decreased rate for the need for permanent shunt placement was reported when low-dose urokinase or fibrinolytic therapy with tPA was used for ventricular irrigation and clot reduction. 32, 61, 75, 77 Reviews conducted by Whitelaw and Odd 74 have also revealed that intraventricular injection of streptokinase has not been shown to be beneficial. 74 A single case re- Frequency & mortality of Grades III & IV hemorrhage in infants weighing btwn 500 & 700 g remained relatively constant over the 3-yr period. Authors concluded that there was a significant reduction in morbidity & mortality associated w/ LBW infants when they began using reservoirs instead of EVDs.
Hudgins et al., 1997 Use of urokinase via reservoir to treat PHH in 18 pts. 4 different doses of urokinase; ultimately grouped into "high" (n = 9) & "low" dose (everyone else, n = 9). Both groups compared to historical control group w/ respect to outcome & need for shunt. Prospective, case control.
Class II Prospective, nonrandomized, case-control series.
Division of 9 pts into "low" dose group would appear to dilute statistical power despite statistical significance obtained. "Low dose" urokinase reduced shunt rate (71% vs 92%) compared to historical controls. Fewer shunt revisions in both groups compared to control group.
Lam & Heilman, 2009 Single-institution, retrospective historical cohort study of 32 preterm infants w/ PHH. This study compared 2 cohorts of infants: those treated w/ VAD/Ommaya placement vs those treated w/ VSG shunts. There were no statistical differences in age or birth weight of the infants in the 2 groups. The groups were studied for IVH grade, need for daily CSF withdrawal, CSF leak from the scalp, CSF infection, & need for a VP shunt. There was a trend toward VP shunt independence in the VSG shunt group, as compared to the VAD group, but it did not reach significance.
VSG shunts decreased the need for daily taps. There was a slightly higher rate of complications in the VSG shunt group, but it was not significant. No morbidity or mortality occurred as a result. 7 of 11 pts required a shunt. 2 of 11 did not require a VP shunt.
Class III Small retrospective case review.
EVD via a subcutaneously tunneled catheter was found to be a safe & reliable initial method of treating PHH in premature infants.
(continued) There was no significant difference in outcome between infants treated w/ VAD or VSG shunts.
(continued) port of intravenous streptokinase, published in 1998, suggested that there may be some benefit. 45 This report was followed by an early Class III study that found benefit in a nonrandomized cohort of preterm infants with PHH who were treated with intravenous low-dose streptokinase. 76 However, data from a later Class II study led to the conclusion that routine use of intraventricular streptokinase in PHH was not recommended. 79 These studies were included in the 2007 Whitelaw and Odd Cochrane review, 74 which argues against intravenous streptokinase for the treatment of PHH in preterm infants (Table 3) .
Despite increased short-term morbidity and recurrent IVH, some benefits were noted in the DRIFT survivors.
72
In the most recent Whitelaw study, 72 the reduction in the primary long-term outcome-death or severe disabilityat 2 years in the DRIFT group reached statistical significance when adjusted for sex, birth weight, and grade of IVH. Severe cognitive disability also was reduced, and this improvement in cognitive function was statistically significant. There was also a reduction in severe sensorimotor disability with DRIFT, but this clinical improvement did not reach statistical significance. The authors hypothesized that the greater effect on cognitive rather than sensorimotor function may be attributed to paren- Single-blind prospective study. 12 preterm infants who developed PHH were randomly assigned to the control group (no treatment) or to receive intraventricular streptokinase (×3 days). Note: the streptokinase group also had an LP (10-15 ml) prior to treatment & then daily LPs (5-10 ml). They also received intraventricular vancomycin. Primary outcome: VP shunt placement.
Class II Small randomized, prospective study 5 of 6 infants in the streptokinase group & 3 of 6 in the control group required VP shunts. No complications were noted. Routine use of intraventricular streptokinase in PHH was not recommended.
Richard et al., 2001
Single-institution experience w/ Ommaya reservoir in 64 pts. 17 pts received fibrinolytic therapy through Ommaya reservoir.
Class III Retrospective case series. Statistics performed on fibrinolytic therapy subgroup, which consisted of 2 different agents w/ multiple doses. Fibrinolytic subgroup then mixed back into overall outcome analysis.
Fibrinolytic therapy led to statistically significant lower rate of shunt placement (31% vs 87%).
Whitelaw et al., 2003
Prospective Phase I trial of new treatment methodology (DRIFT) for prevention of PHH of prematurity. Data from 24 pts compared w/ historical controls. After our review of the literature, we found two Class I studies that reported that preterm infants with a diagnosis of PHH who were treated with acetazolamide and furosemide demonstrated higher risks of neurological complications, morbidity, and mortality (Table 4) . 34, 37 The International Posthemorrhagic Ventricular Dilation (PHVD) Drug Trial Group reported that administration of acetazolamide plus furosemide leads to higher rates of shunt placement (relative risk 1.42) and morbidity (84% vs 60%) compared with standard therapy. 34 Kennedy et al. 37 reported that treatment of PHVD with acetazolamide and furosemide did not decrease the rate of shunt placement (64% in the acetazolamide/furosemide group vs 52% in the control group, not treated with acetazolamide/ furosemide). 37 However, treatment was associated with an Prospective study of 9 preterm infants w/ progressive posthemorrhagic ventricular dilation who underwent a 48-to 72-hr continuous intraventricular infusion of streptokinase. Outcomes: death, need for shunt, secondary IVH, & infection.
Class III Small, prospective, nonrandomized cohort study (Phase I trial).
All pts survived; only 1 of 9 required a shunt prior to discharge (later reports indicated that a total of 4 of 9 ultimately required shunts). No infections, 1 repeat hemorrhage.
Whitelaw et al., 1996
Phase I study to evaluate safety of tPA in 22 preterm infants w/ posthemorrhagic ventricular dilation. Dosefinding data reported. Treatment of PHVD with acetazolamide and furosemide was not recommended. 37 One Class III study reported this treatment was not associated with VP shunt placement, but the severity of IVH (based on IVH grade) and the patient age at the time of IVH were significantly associated with the need for permanent CSF diversion. 36 Kennedy et al. also noted that the ventricular index at time of entry into trial was the only factor significantly predictive of death or need for shunt, after multiple logistic regression analysis. 37 
Timing of Shunt Placement
StRength of RecommendAtion: There is insufficient evidence to recommend a specific infant weight or CSF parameter to direct the timing of shunt placement in premature infants with PHH. StRength of RecommendAtion: Level III, unclear degree of clinical certainty.
There were two Class III studies which evaluated the lower limits of infant weight at time of initial shunt insertion (Table 5) . 4, 8 A weight of 1500 g was safely used as a criterion for VP shunt placement in the Benzel study. 8 A single Class III study showed that CSF cell count, protein, and glucose levels were not statistically related to the occurrence of shunt failure or infection in the study population. 24 The authors recommended that placement of the shunt be timed when the infant's age, weight, and overall stability allow. 24 
Endoscopic Third Ventriculostomy
RecommendAtion: There is insufficient evidence to recommend the use of endoscopic third ventriculostomy (ETV) in premature infants with PHH. StRength of RecommendAtion: Level III, unclear degree of clinical certainty.
Although ETV was discussed in several full-text ar- ticles that we reviewed, there was insufficient evidence available for us to make a recommendation for or against its use for the treatment of PHH in premature infants (Table 6 ). Endoscopic third ventriculostomy for the treatment of hydrocephalus in infants and children will be discussed more thoroughly in subsequent chapters (in particular, Part 4). 42 
Excluded Studies
We excluded 1 Class III study for low "preterm" patient representation (7 patients); in the review of 52 consecutive ETV procedures in 49 infants with hydrocephalus, most infants (31 patients) had aqueductal stenosis. 20 Of the 7 infants with preterm PHH, 6 required a shunt even after ETV. Infants with PHH from premature birth did not benefit from ETV. 20 We excluded another Class III study including patients with different etiologies for hydrocephalus. 44 Although ETV was successful in 57% of patients (8 of 14) , the majority of those infants had congenital aqueductal stenosis without PHH. In the remaining 6 patients, a VP shunt was needed. In 1 Class III single-institution retrospective case series, 18 preterm infants with PHH were treated initially with Ommaya reservoir placement: 1 patient died, 5 patients received a VP shunt, and 9 patients underwent ETV. 56 Three patients did not require any further intervention. While overall, 59% were shunt free at the last follow-up, 5 of the 9 patients who were treated with ETV had to undergo repeated surgery for VP shunt placement. The authors recommended combining placement of an Ommaya reservoir with ETV to reduce shunt dependency for preterm infants with PHH. 56 There was a large (101 patients) Class III multicenter, retrospective study evaluating the success rate of ETV in patients with hydrocephalus from subarachnoid hemorrhage, IVH, and/or CSF infection; a minority of the patients (25% [25 of 101]) had PHH of prematurity. 65 Overall, ETV was successful in 52% of the infants with PHH of prematurity. Endoscopic third ventriculostomy was successful in 100% (13 of 13) of children with a his- Class III Case series of infants treated w/ an ETV. Infants were followed up for 68 mos on average. 6 of the 7 infants w/ PHH from premature birth required a shunt.
Authors concluded that the success rate of 69.4% indicates that ETV is safe & effective in infants w/ hydrocephalus not associated w/ PHH & prematurity. Infants w/ PHH from premature birth did not benefit from ETV.
Lipina et al., 2008
Retrospective consecutive case series of 14 infants <6 mo of age presenting w/ obstructive hydrocephalus. 8 of 14 pts had PHH. ETV was considered successful when a VP shunt was not necessary.
Class III This study included a small number of pts w/ very different etiologies for hydrocephalus.
ETV was successful in 57% of pts-the majority of them w/ primary aqueductal stenosis. In the remaining 6 pts, a VP shunt was needed.
Peretta et al., 2007
Single-institution retrospective review of 18 consecutive preterm infants w/ PHH. Pts were treated w/ placement of an Ommaya reservoir for temporizing ventricular decompression. When necessary, pts later underwent VP shunt placement (n = 5) or ETV (n = 9).
Class III Small single-institution retrospective case series w/ variable treatment patterns. 3 of the surviving 17 infants (17.6%) treated w/ Ommayas did not require additional surgery. 14 of 17 required VP shunt (n = 5) or ETV (n = 9). While additional surgeries were required in the majority of cases, 59% of pts were shunt free at the last follow-up.
Recommended combining Ommaya placement w/ ETV. It reduces shunt dependency in this condition.
Siomin et al., 2002
Multicenter retrospective case series of 101 pts who underwent ETV for hemorrhage or infection. Both pediatric & adult pts included. Of the 101 pts, 25 were treated for PHH of prematurity, & specific data were reported for this cohort. Successful ETV was defined as no further hydrocephalus operations required.
Class III Multicenter study w/ a minority of pts (25%) w/ PHH of prematurity.
ETV was successful in 52% of pts w/ PHH of prematurity. Note: ETV was successful in 13 of 13 of pts w/ PHH who were previously treated w/ a shunt, whereas it was unsuccessful in 12 of 12 pts treated w/ ETV as the firstline treatment. ETV was not successful in pts w/ both hemorrhage & infection.
tory of preterm PHH, even though these patients were initially treated with a shunt. Endoscopic third ventriculostomy was unsuccessful in 12 of 12 infants treated with ETV as the first-line treatment, following preterm PHH.
In patients with both hemorrhage and infection, ETV was not successful.
65
Conclusions
Surgical Temporizing Measures
RecommendAtion: Ventricular access devices (VADs), external ventricular drains (EVDs), ventriculosubgaleal (VSG) shunts, or lumbar punctures (LPs) are treatment options in the management of posthemorrhagic hydrocephalus (PHH). Clinical judgment is required. StRength of RecommendAtion: Level II, moderate degree of clinical certainty.
The evidence demonstrates that VADs reduce morbidity and mortality compared with EVDs.
Routine Use of Serial Lumbar Punctures
RecommendAtion: The routine use of serial lumbar puncture (LP) is not recommended to reduce the need for shunt placement or to avoid the progression of hydrocephalus in premature infants. StRength of RecommendAtion: Level I, high clinical certainty.
Nonsurgical Temporizing Measures
RecommendAtion: Intraventricular thrombolytic agents including tissue plasminogen activator (tPA), urokinase, or streptokinase are not recommended as methods to reduce the need for shunt placement in premature infants with PHH. StRength of RecommendAtion: Level I, high clinical certainty.
RecommendAtion: Acetazolamide and furosemide are not recommended as methods to reduce the need for shunt placement in premature infants with PHH. StRength of RecommendAtion: Level I, high clinical certainty.
Timing of Shunt Placement
RecommendAtion: There is insufficient evidence to recommend a specific weight or CSF parameter to direct the timing of shunt placement in premature infants with PHH. Clinical judgment is required. StRength of RecommendAtion: Level III, unclear clinical certainty.
Endoscopic Third Ventriculostomy
RecommendAtion: There is insufficient evidence to recommend the use of endoscopic third ventriculostomy (ETV) in premature infants with PHH. StRength of RecommendAtion: Level III, unclear clinical certainty.
